Full Press Release Details
Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting.
IRD
Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
Key Takeaway: Ocuphire’s APX3330 for Retinal Diseases to be Presented at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+140%
120-day peak, hindsight
Typical move
6.3%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
APX3330
Phase 2 · Diabetic Retinopathy